Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
212 studies found for:    psoriatic arthritis | psoriatic arthritis
Show Display Options
Rank Status Study
1 Completed A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics
Condition: Psoriatic Arthritis
Intervention: Other: No Intervention
2 Completed
Has Results
Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice
Condition: Psoriatic Arthritis
Intervention:
3 Completed Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment
Condition: Psoriatic Arthritis
Intervention:
4 Active, not recruiting Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment (WPAI))
Condition: Psoriatic Arthritis
Intervention:
5 Completed Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: UCB4940 40 mg;   Drug: UCB4940 80 mg;   Drug: UCB4940 160 mg;   Drug: UCB4940 240 mg;   Drug: UCB4940 320 mg;   Drug: UCB4940 560 mg;   Other: Placebo
6 Recruiting A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Drug: No Intervention
7 Recruiting A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation
Condition: Psoriatic Arthritis
Interventions: Biological: adalimumab;   Drug: methotrexate (MTX)
8 Completed
Has Results
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Drug: etanercept
9 Completed TIght COntrol of Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Intensive management or Tight control;   Drug: Standard management - Control group
10 Completed Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention:
11 Recruiting Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention:
12 Active, not recruiting
Has Results
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 30 mg;   Drug: Placebo
13 Recruiting Efficacy of Golimumab in Combination With Methotrexate (Mtx) Versus Mtx Monotherapy, in Improving Dactylitis, in Mtx naïve Psoriatic Arthritis Patients
Condition: Psoriatic Arthritis
Interventions: Drug: Golimumab;   Drug: Methotrexate;   Drug: Placebo
14 Active, not recruiting Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Drug: Secukinumab
15 Completed Metformin in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Metformin;   Drug: Placebo
16 Recruiting Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Biological: Secukinumab
17 Completed Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)
Condition: Psoriatic Arthritis
Intervention: Drug: adalimumab
18 Terminated AMG 827 in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: AMG 827;   Drug: Placebo
19 Completed Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: Placebo
20 Completed Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Biological: AIN457A

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.